Systematic Analysis of Chemokines Reveals CCL18 is a Prognostic Biomarker in Glioblastoma

Wenqing Gao, Yuanyuan Li, Teng Zhang, Jianglong Lu, Jiasong Pan, Qi Qi, Siqi Dong, Xiangjun Chen, Zhipeng Su, Jixi Li

1State Key Laboratory of Genetic Engineering, Department of Neurology, Huashan Hospital and Institute of Neurology, School of Life Sciences, Shanghai Engineering Research Center of Industrial Microorganisms, Fudan University, Shanghai, 200438, People's Republic of China; 2Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China; 3Department of Neurology, Huashan Hospital and Institute of Neurology, Fudan University, Shanghai, 200040, People's Republic of China; 4National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China

*These authors contributed equally to this work

Correspondence: Zhipeng Su; Jixi Li, Email drsuzhipeng@wmu.edu.cn; ljjixi@fudan.edu.cn

Background: Glioblastoma (GBM) is the most common and aggressive brain tumor in adults, in which chemokines are often upregulated and may play pivotal roles in their development and progression. Chemokines are a large subfamily of cytokines with leukocyte chemotactic activities involved in various tumor progression. However, gene expression patterns of the chemokines on a global scale were not known in GBM.

Methods: Differentially expressed chemokine genes in glioma and normal samples were screened by using The Cancer Genome Atlas (TCGA) database. Cox regression identified the prognosis-related genes in each glioma subtype. The protein expression levels of chemokines in 72 glioma tissues were detected by ELISA.

Results: We found that the transcripts of seven chemokines, including CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, and CXCL13, were highly expressed in GBM that evidenced by involving immune cell infiltration regulation and accompanied with worse outcomes of GBM patients. The prognostic nomogram construction demonstrated that CCL18 held the highest risk score in patients with GBM. Furthermore, experiments on 72 glioma tissue samples confirmed that CCL18 protein expression was positively associated with tumor grade and IDH1 status but inversely with glioma patients’ overall survival (OS).

Conclusion: Our study reveals comprehensive and comparable roles of chemokine members in glioblastoma, and identified CCL18 as a critical driver of GBM malignant behaviors, therefore providing a potential target for developing prognosis and therapy in human glioblastoma.

Keywords: chemokines, GBM, biomarker, overall survival, prognosis

Introduction

Glioblastoma (GBM) is the most common primary malignant tumor in the brain, with an incidence rate of approximately 3.47 per 100,000 people.1 GBM, the World Health Organization (WHO) grade IV glioma, has the worst prognosis.2 Though there are varieties of approved treatments for GBM, including surgical resection, radiotherapy, and chemotherapy, the clinical outcome remains dismal.3 For primary GBM patients, the median overall survival (OS) time was eight months with 95% confidence intervals, and the five-year survival rate was only about 6.8%.1 The possible reasons are the highly invasive nature of GBM cells, the chemotherapeutic drugs due to the blood-brain barrier (BBB).4,5 Many prognosis biomarkers for GBMs have been developed, such as mutations in isocitrate dehydrogenase (IDH) genes, MGMT gene promoter methylation status, chromosome 1p/19q deletion, and tumor protein P53 mutation.1,2 In the WHO 2016 classification, secondary glioblastomas with an IDH mutation originate from lower grade precursor lesions.2 Significantly, mutations in IDH1 are correlated with a better prognosis. However, these mutations are rarer in primary
GBM than in most common adult gliomas. Moreover, antiangiogenic treatments like anti-VEGFR/VEGF drugs do not have significant improvement in survival. Monoclonal antibody bevacizumab might improve life quality, but not OS or progression-free survival (PFS) of GBM patients. Consequently, further efforts are urgently needed to understand the biological behavior of GBM and develop novel methods for diagnosis and treatments.

The tumor microenvironment (TME), one of the critical factors of GBM development and treatment, is the primary interaction location between tumor cells and the host immune system. Through interactions between chemokines and chemokine receptors, different immune cell subsets are recruited into the TME. The chemokines are the largest subfamily of cytokines. They can be further subdivided into four main classes depending on the first two cysteines (C) residues in their protein sequences: namely, the CC-chemokines, the CXC-chemokines, the C-chemokines, and the CX3C-chemokines. Chemokines are also described functionally as inflammatory, homeostatic, or dual-function chemokines. Their ligand-receptor relationships are promiscuous, with a single ligand-binding different receptor and vice versa. Recently, chemokine signaling pathways associated with gliomas have been reviewed. Specific chemokines have distinct effects on tumor growth, metastasis, the low to high-grade gliomas transition, and therapeutic outcomes. Especially, high-risk GBM patients exhibited higher expression level of CCL18, which correlated with high levels of Tim-3, indicating an association between immune cell infiltration and GBM prognosis. However, a systematically contrastive analysis of the role of chemokines in human glioma prognosis is limited. Considering that the chemokine network is highly complicated, it seems unlikely that any single chemokine could be a tumor marker sufficiently effective for GBM diagnosis. Therefore, using a novel combination of multiple biomarkers was proposed as an alternative way to diagnose of patients with GBM.

The aim of this study is to investigate the prognostic value of chemokines in GBM precisely and provide a model for clinical diagnosis. Our analytic workflow follows the standard bioinformatics studies and is briefly outlined in Figure S1. Using the cancer genome atlas (TCGA) data, we explored the comprehensive roles of chemokines in GBM. For the first time, the study comprehensively provided the expression of the whole family of chemokine members, and compared their impacts on GBM. Our results indicated that seven chemokines, including CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, and CXCL13, could serve as prognostic factors for predicting the prognosis of GBM patients. Furthermore, the ELISA assay and the Kaplan-Meier plotter analysis for protein expression level in a cohort of glioma patients confirmed that CCL18 could be a potential independent biomarker in GBM clinical applications, including glioma diagnosis and drug development.

Materials and Methods
Data Processing and Expression Analysis
The mRNA expression data of 42 chemokines (CCL1-5, CCL7-8, CCL11, CCL13-28, CXCL1-3, CXCL5-6, CXCL8-14, CXCL16-17, CX3CL1, XCL1-2) were downloaded from the TCGA database (http://cancergenome.nih.gov/abouttcga), and the respective normal tissue samples were downloaded from the Genotype-Tissue Expression (GTEx, http://gtexportal.org/home/datasets) database. TCGA provided 168 GBM samples containing the prognostic information, while GTEx provided 1157 normal brain tissue samples. For RNA-seq data, expression levels were transcripts per million (TPM) normalized. Expression data for all chemokines were Log2 transformed, and the Wilcoxon rank-sum test was conducted on these tumor types. P < 0.05 was considered to indicate differential expression between tumor and normal tissues. Data analysis was conducted using R software (Version 3.6.3), and the R package “ggplot2” was used to draw box plots.

Survival Analysis
The relationship between each chemokine expression and patients’ prognosis (OS: overall survival) interval in 23 cancers was visualized with forest plots. The hazard ratio (HR) and 95% confidence intervals were calculated via univariate survival analysis. The Kaplan-Meier survival analysis for OS, DSS (disease-specific survival), and PFI (progression-free interval) of seven chemokines (CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, and CXCL13) in GBM via R packages “survminer” and “survival” was conducted to compare the survival difference. We selected the clinical characters of the
age, gender, IDH status, and risk score to construct a prognostic nomogram to help predict the probability of 1- and 2-year OS for GBM patients via R packages “rms” and “survival”. The discrimination of the nomogram was calculated by the concordance index (C-index), and the time ROC analysis was performed by R packages “timeROC” and “ggplot2” to compare the predictive accuracy of gene and risk score. In addition, the prognostic value of seven chemokines (CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, and CXCL13) in GBM was validated through the Chinese Glioma Genome Atlas (CGGA, [http://www.cgga.org.cn](http://www.cgga.org.cn)).

**Immune Response Prediction**

The correlation of the prognosis-related chemokines with levels of immune cell infiltration (including activated dendritic cells, aDCs, B cells, CD8 T cells, cytotoxic cells, DC, eosinophils, immature dendritic cells, idCs, macrophages, mast cells, neutrophils, NK CD56bright cells, NK CD56dim cells, NK cells, plasmacytoid dendritic cells, pDCs, T cells, T helper cells, Tcm, Tem, Th1, Th2, Th17 cells, TReg) was detected in GBM using the R package “GSVA”. Immune cell types were obtained from the article published by Bindea et al. The ssGESA analysis was introduced to quantify the relative infiltration of 24 immune cell types in the GBM microenvironment as described before. In this study, we used $p$-values < 0.05 and $q$-values < 0.2 as the cutoff criteria through R package clusterProfiler.

**GO and KEGG Analysis**

We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of the co-expression genes by R packages “clusterProfile”, “org.Hs.eg.db” and “ggplot”. The clusterProfiler package offers a gene classification method, namely groupGO, to classify genes based on their projection at a specific level of the GO terms, and provides functions, enrichGO and enrichKEGG, to calculate enrichment test for GO terms and KEGG pathways based on hypergeometric distribution. In this study, we used $p$-values < 0.05 and $q$-values < 0.2 as the cutoff criteria through R package clusterProfiler.

**Protein-Protein Interaction (PPI) Network**

A PPI network was conducted based on DEGs using the STRING database ([http://string-db.org](http://string-db.org)) and visualized by R packages “igraph” and “ggraph”. The cut-off value was defined as an interaction score (median confidence) of 0.4.

**Clinical Glioma Samples**

We used 72 glioma samples (15 WHO grade II gliomas, 14 WHO grade III gliomas, and 43 WHO grade IV GBM) to validate the results found from the database materials. In order to keep the comparative analysis consistent and focus on the validation of prognosis biomarkers in GBM (G4), we grouped grade II and grade III tumors together as G2 & G3, comparing with G4 in both mRNA and protein levels. The study complied with the Declaration of Helsinki and was reviewed and approved by the Ethics Committee of the Wenzhou Medical University, China. Written informed consent was obtained from all patients, their next of kin, or another surrogate decision-maker, as appropriate. Clinical specimens were obtained from glioma patients who underwent surgery at the Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, between July 2015 and March 2020. All involved patients were 18 to 77 years old, had detailed clinical history and follow-up information, and had no prior radiotherapy to the brain and no intracranial abscess within six months before surgery.

**ELISA Analysis**

The enzyme-linked immunosorbent assay (ELISA) kits for CCL2, CCL18, and CXCL5 were purchased from ABclonal Biotechnology Co., Ltd. Total protein was extracted with a RIPA buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100 and 1% sodium deoxycholate) supplemented with protein inhibitors (Roche, Switzerland). The relative levels of chemokines (CCL2, CCL18, and CXCL5) in tissue lysates were firstly quantified by the ELISA kits according to manufacturer’s instructions, and then normalized to that of β-actin. We compared the expression level for...
each chemokine at different grades (G2 & G3 vs G4), IDH1 status (wild-type vs mutant), gender (female vs male), and Ki67 values (< 30% vs ≥30%).

Statistical Data
All the data of gene expression was normalized by log2 transformation. Comparison of normal tissue and cancer tissue were used the Wilcoxon rank-sum test. The Kruskal–Wallis test was adopted to analyze the associations between clinical phenotypes and expression levels of 42 chemokines in GBM. The correlation analysis between the two variables was used with the Spearman’s or Pearson’s test. In the survival analysis, the HRs and p values were calculated by the univariate Cox regression analysis or Log rank test. Kaplan-Meier curves were used to compare the survival of patients stratified according to different levels of each chemokine expression. p < 0.05 was set as the significance threshold for all statistical analyses.

Results
Increased Chemokines Expression Levels in GBM
We compared the transcriptional levels of all chemokines in GBM with those in normal samples by using the GTEx and TCGA databases. Patient demographics and clinicopathological characteristics for all patient cohorts used in our study are shown in Table S1. The mRNA expression levels of five members of the CCs subfamily, including CCL15, CCL19, CCL21, CCL24, and CCL28, were significantly downregulated in patients with GBM, while 16 of 24 CCs were overexpressed in GBM versus normal tissues (Figure 1A). As for the other subfamilies of chemokines, the mRNA expression levels in most members of CXCs, XCs, and CX3CL1 were significantly elevated in GBM, except that CXCL17 was reduced significantly (Figure 1B). The pathological stage analyses revealed the expression levels of CCL1-3, CCL5-14, CCL18-27, CXCL1-3, CXCL6-11, CXCL13-16, CX3CL1, and XCL1-2 regularly fluctuated between each of the two different grades (Figure 1C). Compared with grade 2 and grade 3 gliomas (G2, G3), higher expression of CCL2, CCL5-8, CCL13-14, CCL18, and CCL22-26 occurred in GBM (G4) (Figure 1C). Moreover, the results showed that 11 of 14 CXCLs (except CXCL5, CXCL12, and CXCL17), CX3CL1, and XCLs mRNA expressions in patients with GBM were higher than those in patients with G2 and G3 gliomas (Figure 1D). IDH gene status has been considered an effective factor in predicting the overall survival (OS) of glioma patients. Therefore, we compared each chemokine expression in different IDH statuses of GBM from the TCGA database. Higher expressions of CCL2, CCL26, CCL28, CXCL5, CXCL10-11, CXCL14, and XCL1 were found in IDH wild-type GBM (Figure 1E and F). However, only two chemokines, CCL19 and CCL21, had lower expression levels in IDH wild-type gliomas (Figure 1E). The above results showed that the expression of almost all chemokines upregulated significantly with the increase of tumor malignancy.

Identification of Seven Prognosis-Related Chemokines in GBM
Following the univariate Cox regression analysis, CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, and CXCL13 were found to have significant prognostic correlations with OS (overall survival) (Figure 2A). Next, the Kaplan-Meier Plotter tool was used to analyze the correlation between the mRNA levels of chemokines and the survival of patients with GBM. The results revealed that the increased mRNA levels of CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, and CXCL13 were significantly associated with lower disease-specific survival (DSS) (p < 0.05) of all of the patients with GBM (Figure 2B). Analysis of progress-free interval (PFI) data revealed associations between high expression levels of CCL2, CCL8, CCL18, and CXCL5 with the poor prognosis in patients with GBM (Figure 2C). Furthermore, the factors including age, gender, IDH status, the expression level of CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, CXCL13, and risk score, were enrolled to construct a prognostic prediction nomogram to predict the 1- and 2-year survival probability of patients with GBM (Figure S2A). The nomogram showed that IDH status in GBM contributed mostly to prognosis, followed by CCL18 expression level. Each level of every variable was assigned a score on the point scale, and a total score was obtained by adding the scores for each of the selected variables (Figure S2A). Next, to evaluate the predictive efficiencies of CCLs and CXCLs in the 1- and 2-year survival rates in GBM, we performed a receiver operating characteristic (ROC) curve analysis using the TCGA dataset. For CCL2, CCL8, CCL18, and CCL28 at 1-year
stage, the area under the curve (AUC) was 0.65 (95% CI, 0.561 to 0.738), 0.594 (95% CI, 0.501 to 0.687), 0.631 (95% CI, 0.541 to 0.722), and 0.6 (95% CI, 0.508 to 0.691), respectively (Figure S2B). For CXCL1, CXCL5, and CXCL13 at 1-year stage, AUC was 0.651 (95% CI, 0.561 to 0.740), 0.643 (95% CI, 0.553 to 0.733), and 0.57 (95% CI, 0.473 to 0.667), respectively (Figure S2C). These results suggested the appreciable reliability of chemokines as biomarkers for GBM prognosis, and CCL18 exhibited the best accuracy among these seven chemokines.

Relations Between the Prognosis-Related Chemokines with Immune Infiltration Levels and Immune Checkpoints

Immune cells in the TME affect the overall survival of cancer patients. Therefore, we investigated the correlation between the prognosis-related chemokines (CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, and CXCL13) expression levels and immune infiltration in GBM. The results showed a positive correlation between the prognosis-related chemokines expressions with poorer prognosis and higher immune infiltration in GBM. As shown in Figure 3A, the strongest positive correlation existed between the CCL2 or CXCL5 expression and infiltrating levels in macrophages (correlation = 0.742 and 0.707, respectively; all p < 0.001). In addition, the mRNA expression levels of all seven chemokines were appreciably positively correlated with the infiltration levels in macrophages, neutrophils, iDC, DC, Th1 cells, cytotoxic cells, T cells, mast cells, and eosinophils in GBM (marked in green rectangles). In contrast, CCL28 and CXCL13 had weaker correlations with the infiltration levels of immune cells than other chemokines (Figure 3A).
Because chemokine networks affect tumor immunity and tumorigenesis by regulating tumor microenvironment, \(^{23}\) we next calculated the correlations of chemokines with each other in patients with GBM. The results indicated significant \((\text{correlation} > 0.6 \text{ and } p < 0.001)\) and strong positive correlations in the following prognosis-related chemokines: CCL2 and CCL8, CCL5 and CCL8, CCL7 and CCL18, CCL13 and CCL18, CCL1 and CCL7, CXCL1 and CCL20, CXCL5 and CXCL1-3, CXCL5 and CCL2, CCL7, CCL13, or CCL20 (Figure 3B). Furthermore, we calculated the correlations between prognosis-related chemokines expression and immune checkpoint molecules using the spearman’s method. The results showed that both CCLs and CXCLs expression levels were significantly associated with most checkpoint molecules, including TNFRSF14, LAIR1, TNFSF4, CD244, ICOS, CTLA4, CD48, CD28, CD200R1, HAVCR2, and CD80 in GBM \((\text{all } p < 0.05, \text{ Figure 3C})\). Therefore, these results further confirmed that the prognosis-related chemokines were significantly correlated with immune infiltrating cells in GBM, suggesting that chemokines might play vital roles in the GBM microenvironment.

Enrichment Analyses and the PPI Network Construction Among Correlated Genes

As CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, and CXCL13 could be potential prognostic biomarkers for GBM patients, we next identified the differentially expressed mRNAs (DEmRNAs) in GBM samples with these chemokines high and chemokines low expression groups as well as in GBM and adjacent normal tissues using the TCGA database with \(p < 0.05\) and \(|\log \text{fold change } [FC]| > 1\) as the mRNA threshold. Volcano plots visually displaying the distribution of DEmRNAs were generated for seven prognosis-related chemokines, respectively \((\text{Figure 4A–C})\). The relative expression values of the top 15 differentially expressed genes (DEGs) between the two cohorts are shown in Figure 4B–D. Moreover, the Venn diagrams showed that 89 genes were differentially expressed in CCL2, CCL8, CCL18, and CC28.
datasets (Figure 4E). 229 overlapped DEGs were identified that were differentially expressed both in CXCL1, CXCL5, and CXCL13 datasets (Figure 4F).

Next, the common DEGs were compared between CCLs and CXCLs datasets, which were visualized through a Venn diagram (Figure 5A). The number of common DEGs was 64, which accounted for 25.19% of a total of 254 differentially expressed genes. Also, the functional enrichment analysis (GO and KEGG) was performed for 64 common DEGs to explore the potential functions associated with the common regulatory network. It showed that the 64 DEmRNAs participating in the network were mainly enriched in the “cytokine-cytokine receptor interaction”, “leukocyte migration”, “viral protein interaction with cytokine and cytokine receptor”, “myeloid leukocyte migration”, “leukocyte chemotaxies”, and “collagen-containing extracellular matrix” (Figure 5B). Then, to determine whether the 64 genes were associated with GBM prognosis, we used the Kaplan-Meier analysis and a Log rank test to perform OS analysis of GBM patients. In total, 17 DEmRNAs (VDR, MLPH, IL6, C5orf46, RARRES1, MCEMP1, LRRC15, RFX15, ADTRP, AQP9, PF4V1, HAS1, IL7R, HTR3A, SAA2, MARCO, and CD300E) were found to be related to prognosis based on $p < 0.05$.
Figure 4 Volcano plots and heatmap plots of DEmRNAs between the expression of chemokine<sup>high</sup> and chemokine<sup>low</sup> in GBM samples. (A–D) Differentially expressed genes for high expression of the prognosis-related chemokines vs low expression of the prognosis-related chemokines in GBM were shown in the volcano plots. Red represented upregulated genes, and blue indicated downregulated genes. Heatmaps of differentially expressed genes were shown in the lower panel. 15 significant DEGs were shown for each chemokine. (E) Common differentially expressed genes representation through Venn diagrams. 89 genes were found commonly from CCL2, CCL8, CCL18, and CCL28 datasets. (F) 229 genes were found commonly from CXCL1, CXCL5, and CXCL13 datasets. *p < 0.05, **p < 0.01, ***p < 0.001.
The subsequent functional enrichment analysis of the 17 genes revealed that they were strongly associated with "cytokine-cytokine receptor interaction", "hematopoietic cell lineage", "viral protein interaction with cytokine and cytokine receptor", "FoxO signaling pathway", and "JAK-STAT signaling pathway" (Figure 5C). In the protein-protein interaction (PPI) network, the hub genes were positively correlated with the prognosis-related chemokines (interaction score > 0.4) (Figure 5D). MARCO, VDR, LRRC15, SAA2, MCEMP1, PF4V1, IL7R, IL6, and AQP9 were highlighted in the module network as these nine genes were the prognosis-related common DEGs in GBM (Figures 5D and S3).

High CCL18 Protein Expression in GBM Tissues Led to Poor Prognosis in Glioma Patients

Among the seven prognosis-related chemokines discussed above, CCL2, CCL18, and CXCL5 exhibited stronger correlations with clinical outcomes and better prognostic accuracy for glioma patients. Therefore, we analyzed the protein expression levels and prognostic values of CCL2, CCL18, and CXCL5 in 72 glioma patient samples (Table S1). These...
glioma tumors included 15 Grade II (G2), 14 Grade III (G3), and 43 Grade IV (G4) samples. We found that CCL18 and CXCL5, but not CCL2, were more highly expressed in GBM (G4) than in lower grades (G2 and G3) using the ELISA method (Figure 6A–C). Next, we analyzed the protein expression levels of CCL2, CCL18, and CXCL5 with the factors including IDH1 status, gender, and the human tumor cell proliferation marker Ki67 for glioma. Higher CCL18 expression was closely overlapped with IDH1 mutation in the cohort (Figure 6A–C). Besides, the rate of Ki67 proliferation was 1–25% in 35 cases, whereas it was 30–80% in 30 cases with higher CXCL5 expression (Figure 6A–C). Further, the Kaplan-Meier curve and Log rank test analyses revealed that only increased CCL18 protein level was significantly associated with the overall survival (OS) of all patients with glioma (Figure 6D). We next calculated the correlation of three chemokines (CCL2, CCL18, and CXCL5) with each other by analyzing their protein expressions levels in our cohort, which indicated significant and positive correlations in each tested pair (Figure 6E).

Figure 6 The protein expression levels of CCL2, CCL18, and CXCL5 in 72 human glioma tissues. (A–C) Quantification of indicated protein expression levels in patients grouped by G2 & G3 gliomas and GBM (G4), IDH1 wild type and mutant, female and male, low Ki67 rate (<30%) and high Ki67 rate (≥30%), respectively. The relative CCL2, CCL18, and CXCL5 protein levels of human glioma tissue lysates were firstly measured by ELISA and then normalized to that of β-actin. (D) Kaplan-Meier OS curves (High vs Low) for patients stratified by different protein levels of CCL2, CCL18, and CXCL5 in gliomas. (E) Correlation between CCL2, CCL8, and CXCL5 expression in our cohort. All data are representative of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.0001, ns, no significance.


**Discussion**

Chemokines participate in antitumor immune response and form a gradient that can chemoattract leukocytes to the site of damage or infection. On the contrary, chemokines affect tumor progression through various mechanisms that directly affect cancer cell proliferation, or indirectly regulate angiogenesis and recruitment of immune cells that facilitate tumor growth and metastasis. For example, CCL2 inhibits apoptosis of endothelial cells by directly binding receptors CXCR4 and CCR2 that expressed on tumor vessels. CCL18 directly influences tumor cells by promoting invasion, metastasis, and EMT in breast cancer, pancreatic cancer, ovarian cancer, and prostate cancer. Among heterogeneous primary tumors of the central nervous system (CNS), gliomas are the most frequent type, with glioblastoma multiforme (GBM) characterized with the worst prognosis. Previous studies showed that some chemokines were significantly related to prognosis and might be potential biomarkers for GBM, including CXCL1, CXCL5, CXCL10, CXCL11, CXCL14, CCL2, CCL11, CCL13, CCL21, CCL22, CCL27 (Table S2). However, different numbers of GBM samples from the TCGA database were used to analyze the expression of chemokines, making it challenging to identify promising biomarkers for GBM. Thus, accurate survival prediction through a comprehensive analysis of chemokines is essential for GBM patients.

We here analyzed the high-throughput RNA-seq data from the TCGA database to identify 42 differential expressed chemokines genes. The results showed that the expression levels of 32 chemokines were higher than that in normal tissues, and 27 chemokines were positively correlated with tumor stages in patients with gliomas (Figure 1C and D). The increased expression levels of seven chemokines, CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, and CXCL13, were significantly correlated with poor OS and DSS in all of the patients with GBM, indicating that these chemokines were oncogenic events in GBM (Figure 2). Higher CCL2, CCL28, or CXCL5 expression was also found in IDH-1 wild-type GBM (Figure 1E and F). Moreover, higher expression levels of CCL8, CCL18, CCL28, CXCL1, CXCL5, or CXCL13 predicted shorter 1- and 2-year OS in GBM patients, and each chemokine was an independent predictor of prognosis in GBM (Figure S2A). Importantly, CCL18 might be the most accurate biomarker for GBM than other chemokines, and the Kaplan-Meier curve for overall survival in the Chinese Glioma Genome Atlas (CGGA) database also confirms its power for independently predicting prognosis in GBM (Figure S4).

The microenvironment (TME) plays an essential role in the progression and metastasis of GBM. Generally, TME is enriched for pro-inflammatory cytokines, chemokines, and their complex cross-talk with their receptors influences the development of cancers. For example, macrophages can be recruited into the tumor microenvironment by the CCL2-CCR2 signaling, associated with poor patient prognosis in breast cancer. As a significant cytokine of TAMs, CCL18 immunopositive cells represent a subset of macrophages in breast cancer tissues. Besides, CXCL5 binds to its receptors CXCR2 in TME to participate in the recruitment of immune cells, promoting tumor growth and metastasis. In our study, immune cell infiltration analysis demonstrated that the prognosis-related chemokine members (CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, CXCL13) were significantly associated with different immune cells, especially with macrophages among 24 immune cells in GBM (Figure 3). Previous studies showed that high-grade murine gliomas harboring a mutant IDH1 allele exhibited reduced macrophage infiltration, which correlated with lower chemokine expression levels. Also, CCL2 is produced by the tumor cells, which attract macrophages in experimental glioblastoma models. Combined with our results, we proposed that the prognosis-related chemokines might be involved in the recruitment of immune cells or partly derived from macrophages, deteriorating tumor microenvironment, inhibiting prolonged survival of GBM patients.

The functional enrichment analysis showed that the 64 common gene sets associated with the seven prognosis-related chemokines in GBM were mainly enriched in cytokine-cytokine receptor interaction and leukocyte migration. Our Kaplan-Meier survival analysis revealed that 17 of 64 common gene expressions were significantly associated with a poor prognosis for OS, involved in the JAK-STAT signaling pathway and the FoxO signaling pathway (Figure 5). This result further confirmed the efficacy of CCL2, CCL8, CCL18, CCL28, CXCL1, CXCL5, and CXCL13 as prognostic indicators of GBM.

Many pan-cancer analysis studies revealed some hallmarks of different cancers, including the genetic and metabolic alterations. However, these prognostic biomarkers might not be accurate without considering protein translation or post-
translation profiles. We here detected the protein expression levels of CCL2, CCL18, and CXCL15 in 72 glioma tissues, and discovered a remarkably higher expression of CCL18 in the subgroup of G4 glioma compared to lower grade glioma cases (G2 and G3), accompanied by a poor prognosis of glioma patients (Figure 6). Also, the expression of CXCL5 was associated with several clinicopathological parameters in glioma patients (eg, tumor grade and high Ki67 rate), suggesting the critical role in promoting tumor growth (Figure 6).

In conclusion, we comprehensively analyzed the differential expression of four subfamilies of chemokines in GBM and evaluated their clinical and prognostic values. We demonstrated that CCL18 could be an accurate, independent prognostic factor for glioma patients, while other prognosis-related chemokines (CCL2, CCL8, CCL28, CXCL1, CXCL5, and CXCL13) might be an additional diagnostic biomarker. It can be speculated that these prognosis-related chemokines, especially CCL18, could become therapeutic targets for GBM treatment.

Data Sharing Statement
The datasets generated and analyzed during this study are available in the public database TCGA, GTEx, and CGGA. The patients involved in the database have obtained ethical approval. Additional data and source codes related to this paper may be requested from the corresponding author Jixi Li (lijixi@fudan.edu.cn).

Funding
This work was supported by grants from the National Natural Science Foundation of China (82071782, 31670878) and the Shanghai Committee of Science and Technology (20XD1400800, 22YF1403400).

Disclosure
The authors declare that they have no competing interests in this work.

References
1. Ostrom QT, Patil N, Cioffi G, Waite K, Knuchko C, Barnholtz-Sloan JS. CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22(12 Suppl 2):iv1–iv96. doi:10.1093/neuonc/noaa200
2. Wesseling P, Capper D. WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol. 2018;44(2):139–150. doi:10.1111/nan.12432
3. Janjua TI, Rewatkar P, Ahmed-Cox A, et al. Frontiers in the treatment of glioblastoma: past, present and emerging. Adv Drug Deliv Rev. 2021;171:108–138. doi:10.1016/j.addr.2021.01.012
4. Wu W, Klockow JL, Zhang M, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171:105780. doi:10.1016/j.phrs.2021.105780
5. Iser IC, Pereira MB, Lenz G, Wink MR. The epithelial-to-mesenchymal transition-like process in glioblastoma: an updated systematic review and in silico investigation. Med Res Rev. 2017;37(2):271–313. doi:10.1002/med.21408
6. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11(4):341–347. doi:10.1215/15228517-2009-025
7. Gramatzki D, Roth P, Rushing EJ, et al. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Ann Oncol. 2018;29(6):1431–1436. doi:10.1093/annonc/mdy106
8. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572. doi:10.1038/nri.2017.49
9. Vilgelm AE, Richon A. Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy. Front Immunol. 2019;10:333. doi:10.3389/fimmu.2019.00333
10. Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36(5):705–716. doi:10.1016/j.immuni.2012.05.008
11. Takacs GP, Flores-Toro JA, Harrison JK. Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy. Pharmacol Ther. 2021;222:107790. doi:10.1016/j.pharmthera.2020.107790
12. Urbantat RM, Vajkoczy P, Brandenburg S. Advances in chemokine signaling pathways as therapeutic targets in glioblastoma. Cancers. 2021;13(12):2983. doi:10.3390/cancers13122983
13. Broekman ML, Maas SLN, Abels ER, Mempel TR, Krichevsky AM, Breakefield XO. Multidimensional communication in the microenviron of glioblastoma. Nat Rev Neurosci. 2018;19(8):482–495. doi:10.1038/s41588-018-0025-8
14. Groblewska M, Mroczko B. Pro-and Antiangiogenic factors in gliomas: implications for novel therapeutic possibilities. Int J Mol Sci. 2021;22(11):6126. doi:10.3390/ijms22116126
15. Slattenar VI, Wilson JL. The chemokine network: a target in cancer biology? Adv Drug Deliv Rev. 2006;58(8):962–974. doi:10.1016/j.addr.2006.03.012
16. Cheng W, Ren X, Zhang C, et al. Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 2016;86(24):2226–2234. doi:10.1212/WNL.0000000000002770
17. Zhu Z, Zhang X, Yu Z, et al. Correlation of Tim-3 expression with chemokine levels for predicting the prognosis of patients with glioblastoma. J Neuroimmunol. 2021;355:577575. doi:10.1016/j.jneuroim.2021.577575

---

2742 Journal of Inflammation Research 2022:15

Dovepress

Gao et al

The authors declare that they have no competing interests in this work.
18. Dang HH, Ta HDK, Nguyen TTT, et al. Identifying GPSM family members as potential biomarkers in breast cancer: a comprehensive bioinformatics analysis. *Biomedicines*. 2021;9(9):114. doi:10.3390/biomedicines9091144

19. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity*. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.003

20. Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinform*. 2013;14:7. doi:10.1186/1471-2105-14-7

21. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS*. 2012;16(5):284–287. doi:10.1089/omi.2011.0118

22. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res*. 2019;47(D1):D607–D613. doi:10.1093/nar/gky1131

23. Bhat AA, Niser S, Maacha S, et al. Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. *Mol Cancer*. 2021;20(1):2. doi:10.1186/s12943-020-01294-3

24. Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002;420(6917):860–867. doi:10.1038/nature01322

25. Sallusto F, Baggiolini M. Chemokines and leukocyte traffic. *Nat Immunol*. 2008;9(9):949–952. doi:10.1038/ni.f.214

26. Marcuzzi E, Angioni R, Molon B, Chemokines CR. Chemokine receptors: orchestrating tumor metastasization. *Int J Mol Sci*. 2018;20(1):96. doi:10.3390/ijms20010096

27. Mollica Poeta V, Massara M, Capucetti A, Chemokines BR. Chemokine receptors: new targets for cancer immunotherapy. *Front Immunol*. 2019;10:379. doi:10.3389/fimmu.2019.00379

28. Szekely B, Bossuyt V, Li X, et al. Immunological differences between primary and metastatic breast cancer. *Nat Immunol*. 2008;9(9):949–952. doi:10.1038/ni.f.214

29. Letourneau D, Danlos FX, Marabelle A. Chemokine biology on immune checkpoint-targeted therapies. *Eur J Cancer*. 2020;137:260–271. doi:10.1016/j.ejca.2020.06.009

30. Luo H, Tao C, Wang P, Li J, Huang K, Zhu X. Development of a prognostic index based on immunogenomic landscape analysis in glioma. *Glioma CRC*. 2020;20(1):69–80. doi:10.1002/cac2.12010

31. Fazi B, Proserpio C, Galardi S, et al. The expression of the chemokine CXCL14 correlates with several aggressive aspects of glioblastoma and promotes key properties of glioblastoma cells. *Int J Mol Sci*. 2019;20(10):2496. doi:10.3390/ijms20102496

32. Zhou M, Bracci PM, McCoy LS, et al. Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time. *Int J Cancer*. 2015;137(4):826–836. doi:10.1002/ijc.29441

33. Wang J, Toregrosa-Allen S, Elzey BD, et al. Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells. *Proc Natl Acad Sci USA*. 2021;118(45). doi:10.1073/pnas.2107507118

34. Wang J, Toregrosa-Allen S, Elzey BD, et al. Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells. *Proc Natl Acad Sci USA*. 2021;118(45). doi:10.1073/pnas.2107507118

35. Yang H, Zhang Q, Xu M, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. *Mol Cancer*. 2020;19(1):41. doi:10.1186/s12943-020-01165-x

36. Szekely B, Bossuyt V, Li X, et al. Immunological differences between primary and metastatic breast cancer. *Ann Oncol*. 2018;29(11):2232–2239. doi:10.1093/annonc/mdy399

37. Chen J, Yao Y, Gong C, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. *Cancer Cell*. 2011;19(4):541–555. doi:10.1016/j.ccr.2011.02.006

38. Zhang W, Wang H, Sun M, et al. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. *Cancer Commun*. 2020;40(2–3):69–80. doi:10.1002/cac2.12010

39. Guttman DH, Kettenmann H. Microglia/Brain macrophages as central drivers of brain tumor pathobiology. *Neuron*. 2019;104(3):442–449. doi:10.1016/j.neuron.2019.08.028

40. Jin J, Lin J, Xu A, et al. CCL2: an important mediator between tumor cells and host cells in tumor microenvironment. *Front Oncol*. 2021;11:722916. doi:10.3389/fonc.2021.722916